Funder
Health Technology Assessment Programme
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference19 articles.
1. National Institute for Health and Care Excellence. Etelcalcetide for treating secondary hyperparathyroidism: technology appraisal guidance [TA448]. 2017. Available at:
https://www.nice.org.uk/guidance/ta448
. Accessed 27 Mar 2018.
2. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913.
3. Arbor Research Collaborative for Health. 2012 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1997–2011. 2012. Available at:
http://www.dopps.org/AnnualReport/
.
4. Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.
5. Caskey F, Cullen R. UK Renal Registry 18th Annual Report 2015. Nephron. 2016;132(Suppl 1):1–8.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献